ADRIN SARWAR

In Bangladesh, the reality for thousands of families is the overwhelming physical, emotional, and financial burden of a cancer diagnosis. While the country battles a surge in cases the focus has shifted toward making high-quality treatment both accessible and affordable.

In this evolving landscape, Renata PLC has become a trusted name among patients and clinicians alike. Tracing its origins to Pfizer Bangladesh, which transferred ownership to local shareholders in 1993, the company has made oncology a strategic priority. By developing high-quality, bioequivalent cancer medicines, Renata has introduced notable innovations to the local market, such as Ready-to-Use (RTU) chemotherapy formulations designed to enhance safety and precision.

However, despite these advancements, accessing specialised medication remains a hurdle for many. Most oncology-focused pharmacies are concentrated in major urban centres, leaving patients in rural areas often out of reach. Believing that logistical barriers and physical exhaustion should never stand in the way of life-saving treatment, Renata provides free home delivery of cancer medicines directly from its depots. This service ensures that treatment remains uninterrupted, regardless of a patient’s location.

Beyond accessibility, Renata PLC strengthens cancer care by ensuring every product meets global standards. Through rigorous quality controls across its oncology and haematology portfolio, the company guarantees that high-quality, life-saving medication remains reliable. This focus on clinical research ensures that international benchmarks are met locally. With its mission to “leave no patient behind,” Renata continues to focus on affordable, quality-driven, and patient-centred cancer care in Bangladesh.